These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 7529949)
1. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy. Feindt P; Seyfert UT; Volkmer I; Straub U; Gams E Thorac Cardiovasc Surg; 1994 Aug; 42(4):218-21. PubMed ID: 7529949 [TBL] [Abstract][Full Text] [Related]
2. In vitro effects of aprotinin on activated clotting time measured with different activators. Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640 [TBL] [Abstract][Full Text] [Related]
3. Effects of low doses of aprotinin on clotting times activated with celite and kaolin. Farooqi N; De Hert S; Vlaeminck R; De Bakker A; Govaerts E; Vermeyen K Acta Anaesthesiol Belg; 1993; 44(3):87-92. PubMed ID: 7508668 [TBL] [Abstract][Full Text] [Related]
4. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Wendel HP; Heller W; Gallimore MJ; Bantel H; Müller-Beissenhirtz H; Hoffmeister HE Blood Coagul Fibrinolysis; 1993 Feb; 4(1):41-5. PubMed ID: 7681331 [TBL] [Abstract][Full Text] [Related]
5. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients. Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552 [TBL] [Abstract][Full Text] [Related]
6. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293 [TBL] [Abstract][Full Text] [Related]
7. Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time. Dong Y; Nuttall GA; Oliver WC; Agarwal S; Ereth MH J Clin Anesth; 2007 Sep; 19(6):424-8. PubMed ID: 17967670 [TBL] [Abstract][Full Text] [Related]
8. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements. Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483 [TBL] [Abstract][Full Text] [Related]
9. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Dietrich W; Dilthey G; Spannagl M; Jochum M; Braun SL; Richter JA Anesthesiology; 1995 Oct; 83(4):679-89; discussion 29A-30A. PubMed ID: 7574046 [TBL] [Abstract][Full Text] [Related]
10. Aprotinin and heparin monitoring during cardiopulmonary bypass. Hunt BJ; Segal H; Yacoub M Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011 [TBL] [Abstract][Full Text] [Related]
11. Activated clotting time, anticoagulation, use of heparin, and thrombin activation during extracorporeal circulation: changes under aprotinin therapy. Feindt P; Volkmer I; Seyfert U; Huwer H; Kalweit G; Gams E Thorac Cardiovasc Surg; 1993 Feb; 41(1):9-15. PubMed ID: 7690165 [TBL] [Abstract][Full Text] [Related]
12. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin. Francis JL; Howard C Blood Coagul Fibrinolysis; 1993 Feb; 4(1):35-40. PubMed ID: 7681330 [TBL] [Abstract][Full Text] [Related]
13. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients. Huyzen RJ; Harder MP; Huet RC; Boonstra PW; Brenken U; van Oeveren W J Cardiothorac Vasc Anesth; 1994 Apr; 8(2):153-6. PubMed ID: 7515704 [TBL] [Abstract][Full Text] [Related]
14. Using activated clotting time to estimate intraoperative aprotinin concentration. Iwata Y; Okamura T; Zurakowski D; Jonas RA Perfusion; 2009 Nov; 24(6):397-400. PubMed ID: 20093334 [TBL] [Abstract][Full Text] [Related]
15. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Despotis GJ; Filos KS; Levine V; Alsoufiev A; Spitznagel E Anesth Analg; 1996 Jun; 82(6):1126-31. PubMed ID: 8638779 [TBL] [Abstract][Full Text] [Related]
16. The effects of aprotinin on thromboelastography with three different activators. Avidan MS; Da Fonseca J; Parmar K; Alcock E; Ponte J; Hunt BJ Anesthesiology; 2001 Nov; 95(5):1169-74. PubMed ID: 11684986 [TBL] [Abstract][Full Text] [Related]
17. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Wang JS; Lin CY; Hung WT; Karp RB Anesthesiology; 1992 Dec; 77(6):1080-4. PubMed ID: 1281624 [TBL] [Abstract][Full Text] [Related]
18. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses. Despotis GJ; Alsoufiev AL; Spitznagel E; Goodnough LT; Lappas DG Ann Thorac Surg; 1996 Mar; 61(3):795-9. PubMed ID: 8619695 [TBL] [Abstract][Full Text] [Related]
19. The activated clotting time in cardiac surgery: should Celite or kaolin be used? De Vries AJ; Lansink-Hartgring AO; Fernhout FJ; Huet RCG; van den Heuvel ER Interact Cardiovasc Thorac Surg; 2017 Apr; 24(4):549-554. PubMed ID: 28108578 [TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery. Kim YS; Murkin JM; Adams SJ Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]